Atherogenic oxidative-antioxidants modifications of low density lipoproteins. population study

    The aim of the study was to investigate of parameters of oxidation-antioxidant changes in low density lipoprotein (LDL) in men population and to evaluate their associations with risk factors for atherosclerosis and coronary artery disease (CAD). A population-based survey of 1024 Novosibirsk men 47–73 years old was performed. Programm of the survey included the questionnaires, standardized cardiological survey, anthropometry, blood pressure measurement, ECG recording. In 223 people (21.8 %) had «definitely CHD» (stable angina pectoris, FC II–IV) by a validated epidemiological, clinical and functional criteria. Biochemical studies included the determinations of blood total cholesterol (CH), triglyceride (TG), high density lipoprotein cholesterol (HDL-CH), C-reactive protein in a highly sensitive range (hsCRP), glucose, baseline lipid peroxidation (LPO) and fat-soluble antioxidants (alpha-tocopherol, retinol, beta-carotene, xanthine) in LDL, LDL resistance to oxidation in vitro, the concentration of autoantibodies to oxidized LDL (oxLDL).

   For the Novosibirsk male population as regional values are 10–90 % cut-off point percentile distribution of baseline LPO level in LDL, LDL resistance to oxidation at the initial and propagation stages of their oxidation, lipophilic antioxidants in LDL, concentration of autoantibodies to oxLDL. Elevated level of LPO products in LDL, decreased antioxidants content in LDL and, especially, decreased resistance of LDL to oxidation in men independently associated with elevated blood levels of CH, TG, hsCRP, reduced HDL-CH, increased BMI. Positive correlations and independent associations between decreased LDL resistance to oxidation in vitro and CHD were revealed. Negative correlations between decreased LDL alpha-tocopherol content and CHD were revealed also. The incidence of CHD is higher in the index of the initial level of lipid peroxidation (LPO) in LDL > 0.8 nM MDA/mg LDL protein and decreased resistance of LDL to oxidation (at rates in the initial stage of LDL oxidation > 5.4 nM MDA/mg LDL protein and in the progressive stage of LDL oxidation > 13.2 nM MDA/mg LDL protein). On the other hand, the incidence of CHD is lower in the index of alpha-tocopherol in LDL >1.06 mg/mg protein LDL.

   The results confirm the known data about the key role of LDL oxidative modification in the pathogenesis of atherosclerosis and CHD.

1. Osterud B., Bjorklid E. Role monocytes in atherogenesis // Physiol. Rev. 2003. Vol. 83. 1069–1113.

2. Williams K. J., Fisher E. A. Oxidation, lipoproteins and atherosclerosis // Curr. Opin. Clin. Nutr. Care. 2005. Vol. 8. P. 139–146.

3. Steinberg D. The LDL modification hypothesis of atherogenesis: an update // J. Lipid Res. 2009. Suppl.: P. S376–S381.

4. Stocker R., Keaney J. F. New insights on oxidative stress in the artery wall // J. Thromb. Haemost. 2005. Vol. 3 (8). P. 1825–1834.

5. Menschikova E. B., Lankin V. Z., zenkov N. K. et al. Oxidative stress. Prooxidants and antioxidants. Moscow: Word, 2006, 560 p.

6. De Rosa S., Cirillo P., Paglia A. et al. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? // Curr. Vasc. Pharmacol. 2010. Vol. 8 (2). P. 259–275.

7. Ishigaki Y., Oka Y., Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor // Curr. Opin. Lipid. 2009. Vol. 20 (5). P. 363–369.

8. Esterbauer H., Jurgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation // Curr. Opin. Lipid. 1993. Vol. 4. P. 114–124.

9. Yoshida H., Kisugi R. Mechanisms of LDL oxidation // Clin. Chim. Acta. 2010. Vol. 411 (23-24). P. 1875–1882.

10. Ragino Yu. I., Voevoda M. I., Dushkin M. I. et al. Application of new biochemical methods for evaluation of oxidative-antioxidative potential of low density lipoproteins // Clin. Lab. Diagn. 2005. Vol. 4. P. 11–15.

11. Voevoda M. I., Semaeva E. V., Ragino Yu. I. et al. Lipid and lipoproteins disturbances in coronary atherosclerosis. Comparison with population data // Rus. Cardiol. J. 2005. Vol. 4. P. 58–63.

12. Ragino Yu. I., Polonskaya Ya. V., Semaeva E. V. et al. Atherogenic oxidative and structural modifications of low density lipoproteins in coronary atherosclerosis men // Cardiology. 2007. Vol. 11. P. 14–19.

13. Mitra S., Deshmukh A., Sachdeva R. et al. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy // Am. J. Med. Sci. 2011. Vol. 342 (2). P. 135–142.

14. D’Archivio M., Annuzzi G., Vari R. et al. Predominant role of obesity/insulin resistance in oxidative stress de-velopment // Eur. J. Clin. Invest. 2012. Vol. 42 (1). P. 70–78.

15. Singh U., Jialal I. Anti-inflammatory effects of alpha-tocopherol // Ann. N.Y. Acad. Sci. 2004. Vol. 1031. P. 195–203.

16. Saremi A., Arora R. Vitamin E and cardiovascular disease // Am. J. Ther. 2010. Vol. 17 (3). P. e56–е65.

17. Ragino Yu. I., Krivchun A. S., Ivanova M. V. et al. Oxidative-antioxidants modifications of low density lipo-proteins and their associations with some atherosclerosis risk factors in men population of Novosibirsk // Rus. Cardiol. J., 2012. Vol. 3. P. 56–62.

18. Рагино Ю. И. Связь окислительно-антиоксидантных изменений липопротеинов низкой плотности с ишемической болезнью сердца в популяции мужчин Новосибирска / Ю. И. Рагино [и др.] // Рос. кардиол. журн. – 2013. – № 6 (104). – C. 43–48.